Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05367661 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
A Phase 1 study, sponsored by Chinook Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT05367661 is a Phase 1 study that was terminated before completion, run by Chinook Therapeutics. The registered enrollment target is 88 participants.
The verdict
NCT05367661, a Phase 1 study, was terminated before completion, sponsored by Chinook Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.
Interventions
- DRUG Placebo
- DRUG CHK336
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2022-04-08 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05367661
The ClinicalTrials.gov registry entry for NCT05367661 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chinook Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05367661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05367661 about?
NCT05367661 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers". This study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of an investigational drug (CHK-336) when administered to healthy volunteers.
What is the current status of trial NCT05367661?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2022-04-08. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT05367661?
The interventions under investigation include: Placebo (DRUG), CHK336 (DRUG).
Who is sponsoring clinical trial NCT05367661?
This trial is sponsored by Chinook Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.